Radiotherapy and combination chemotherapy with carmustine,vincristine, and procarbazine (BVP) in primary brain tumors |
| |
Authors: | Giuseppe Comella Gianfranco Scoppa Mariarosaria De Marco Giovanni Pietro Ianniello Giovanni Melillo Francesco Coucourde Donato Zarrilli |
| |
Institution: | (1) Istituto per to Studio e la Cura dei Tumori di Napoli, I Divisione di Medicina, Italy;(2) Istituto per lo Studio e la Cura dei Tumori di Napoli, Divisione di Radioterapia, Italy;(3) Istituto dei Tumori, Capella dei Cangiani, 80131 Napoli, Italy |
| |
Abstract: | Summary 26 patients with astrocytoma grade 11–111, and 36 with malignant glioma (astrocytoma grade IV or glioblastoma) were submitted three days after surgery to a cycle of combination chemotherapy, including BCNU, VCR, PCZ (BVP). Eighteen days after surgery, patients received 40 Gy (astrocytoma grade 11–111) or 45 Gy (malignant glioma) of megavoltage whole-brain irradiation, with an additional boost to the tumor bed of 20 Gy, delivered in 6 weeks. Vincristine was injected weekly during radiotherapy. At the end of radiotherapy, patients received BVP every 6 weeks for at least 8 cycles or until a recurrence or progressive disease. Performance status of grade 1 or 2 was achieved in 15 (60%) and in 5 (20%), respectively, of patients with astrocytoma grade 11–111 after 6 months, and in 6 ps. (29%) and in 9 ps. (42%) after 12 months of follow-up. Only 2 (5.5%) and 18 (64%) patients with malignant glioma achieved a performance status of grade 1 or 2 after 6 months, and these proportions are 6% and 35%, respectively, after 12 months. After a 5-year follow-up, 59% of patients with astrocytoma are still alive, with a median survival time of 60+ months, whereas only 4% of patients with malignant glioma are alive, with a median of 11.2 months. |
| |
Keywords: | malignant glioma radiotherapy chemotherapy |
本文献已被 SpringerLink 等数据库收录! |
|